OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

OSI-906 (Linsitinib) Chemical Structure

OSI-906 (Linsitinib) Chemical Structure
Molecular Weight: 421.49

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

IGF-1R Inhibitors with Unique Features

  • Pan IGF-1R Inhibitor

    GSK1904529A Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • Most Potent IGF-1R Inhibitor

    BMS-754807 IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • IGF-1R Inhibitor in Clinical Trial

    BMS-754807 Phase II for Breast Cancer.

  • Newest IGF-1R Inhibitor

    PQ 401 Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)

 View  More

IC50 35 nM 75 nM 75 nM >10 μM
In vitro OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-FukM1vQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\KVFV2UUN3ME2wMlAzQDB4IN88US=>M{LHNXNCVkeHUh?=
KS-1NFrLe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPLdm1KSzVyPUCuNFM5OzVizszNNVz2T41QW0GQR1XS
TE-11M3G4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjhOJBXUUN3ME2wMlA4QDJ{IN88US=>NWOwV3ZwW0GQR1XS
EW-1M2L1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfwZZpFUUN3ME2wMlA5PTh3IN88US=>NVXlUZlQW0GQR1XS
HMV-IINGnHXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnrbGk{UUN3ME2wMlA5QDR4IN88US=>MlnLV2FPT0WU
COLO-205NE\PbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HHXmlEPTB;MD6xNFQ2PCEQvF2=NHK5[YtUSU6JRWK=
ES1MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTBwMUC2PVYh|ryPM2PySXNCVkeHUh?=
GDM-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rENGlEPTB;MD6xN|Y4OiEQvF2=NX7xTZdkW0GQR1XS
ML-2NVzQXod1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\WeJluUUN3ME2wMlE2QDl4IN88US=>NYHVZ5c1W0GQR1XS
Saos-2M{TmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTPTWM2OD1yLkG2OVI3KM7:TR?=MnfoV2FPT0WU
NCI-H1355NHnUcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\iRXVKSzVyPUCuNVgyOzVizszNMVnTRW5ITVJ?
G-401MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYC2TXdFUUN3ME2wMlE5OjNizszNMV7TRW5ITVJ?
EW-16MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\QTWM2OD1yLkG4O|c4KM7:TR?=NIHUOZNUSU6JRWK=
EW-7M3X1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4q1S2lEPTB;MD6xPFg5OSEQvF2=M3;LbXNCVkeHUh?=
NCI-H727M1nuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnKfIhKSzVyPUCuNVk4QTRizszNNHnhVXZUSU6JRWK=
LCLC-97TM1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwMkC5OVUh|ryPNYjKOm16W0GQR1XS
NCI-H650M2i1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLDSnB5UUN3ME2wMlIyOzh2IN88US=>MUDTRW5ITVJ?
NCI-H2122NUX4TXBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NICzZ3dKSzVyPUCuNlMzQTlizszNNYLjeGVKW0GQR1XS
SK-N-DZNUjrcpNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPNTWM2OD1yLkKzOlk5KM7:TR?=MojsV2FPT0WU
HT-29M3X2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvPO|dKSzVyPUCuNlQzPDhizszNMXPTRW5ITVJ?
LB771-HNCM33jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HNVWlEPTB;MD6yOVkyPSEQvF2=NVnaXnZjW0GQR1XS
HT-144Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrlUZRKSzVyPUCuNlYyQTFizszNMlTKV2FPT0WU
LAN-6NGPxeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknpTWM2OD1yLkK2N|Q5KM7:TR?=NXfGeGRMW0GQR1XS
EW-18M2DoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrKWphKSzVyPUCuNlcxODFizszNNWexclFkW0GQR1XS
LS-1034Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTBwMkexN|Ih|ryPMVXTRW5ITVJ?
EW-11NXK1WlI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnBWI83UUN3ME2wMlI5PDN{IN88US=>NF\JdFFUSU6JRWK=
SNU-C1M4DWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vuemlEPTB;MD6yPVMyOyEQvF2=M1n6NHNCVkeHUh?=
RS4-11NWjLRlh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1z5OmlEPTB;MD6zN|c2QCEQvF2=NIS0OoxUSU6JRWK=
ES4M4rET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC0TWM2OD1yLkSxNFM5KM7:TR?=NW\vSVMzW0GQR1XS
COLO-320-HSRNITKTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4G4ZWlEPTB;MD60NVM3QCEQvF2=M4O4e3NCVkeHUh?=
NB10NGfRfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk[2TWM2OD1yLkS1OFM4KM7:TR?=M3OzZnNCVkeHUh?=
BFTC-905Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj1TWM2OD1yLkS2O|U5KM7:TR?=NHzWUFNUSU6JRWK=
A375M{TCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jVe2lEPTB;MD60O|YyPyEQvF2=M4KxNHNCVkeHUh?=
SJRH30M1fRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPJS5VEUUN3ME2wMlUxQDJ{IN88US=>NHzKN2xUSU6JRWK=
NOS-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTBwNUKyOlch|ryPM{TmVXNCVkeHUh?=
SIG-M5NIjhbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4X3NGlEPTB;MD61N|U2PyEQvF2=NVvEcIk{W0GQR1XS
DOKMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTBwNUW2JO69VQ>?M17yWXNCVkeHUh?=
NB69M4CyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MormTWM2OD1yLkW4NlU4KM7:TR?=MoPlV2FPT0WU
SK-NEP-1NFrkZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTRTWM2OD1yLk[wNlM3KM7:TR?=NF7YUIlUSU6JRWK=
SK-MM-2M3LnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HDZmlEPTB;MD62OVQ6OSEQvF2=MV7TRW5ITVJ?
NCI-H358NFz5PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTSbZRKSzVyPUCuOlcxQDJizszNMV7TRW5ITVJ?
RH-1MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLuTWM2OD1yLke0PFU6KM7:TR?=NEf6cZlUSU6JRWK=
NH-12MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[wV|FKSzVyPUCuO|YxPDZizszNMmDwV2FPT0WU
TE-12M4\hdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nUfmlEPTB;MD63OlQ5PiEQvF2=NFPHNHpUSU6JRWK=
COLO-668Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XVTmlEPTB;MD64OFY3PiEQvF2=MV;TRW5ITVJ?
PANC-08-13MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwOE[zO|ch|ryPNYTZVVZOW0GQR1XS
HCC2998Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHJWXR5UUN3ME2wMlg5OjZ|IN88US=>MmC2V2FPT0WU
ABC-1M3rNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwOUCzOVIh|ryPNH\LXVVUSU6JRWK=
ES6MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjkXIwzUUN3ME2wMlkyODZ4IN88US=>M4TIR3NCVkeHUh?=
SNU-387Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjiNmlHUUN3ME2wMlk6Ozl|IN88US=>M4LFOXNCVkeHUh?=
CMKM3[yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;HU2lEPTB;MD65PVkzQSEQvF2=M1[1NnNCVkeHUh?=
SJSA-1NUHqUmNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT5TWM2OD1zLkCzOlU{KM7:TR?=M1TBW3NCVkeHUh?=
SIMANU\rbIlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDmTWM2OD1zLkC2PFI2KM7:TR?=M2LsTHNCVkeHUh?=
ES3M3L5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;qOIZKSzVyPUGuNVIzQTdizszNMlTJV2FPT0WU
IGROV-1NYrCR4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfPTWM2OD1zLkG1OFQ1KM7:TR?=MXHTRW5ITVJ?
MEL-JUSOMojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHVTWM2OD1zLkG1O|U6KM7:TR?=NWq5UY1EW0GQR1XS
T84M2f0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkSyTWM2OD1zLkKwPVE1KM7:TR?=M{m2[HNCVkeHUh?=
CAL-85-1M4TzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PmeWlEPTB;MT6yN|E{QCEQvF2=NIjPU|ZUSU6JRWK=
RDNFnsfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3xVos3UUN3ME2xMlI3PDV3IN88US=>NV\iPXNGW0GQR1XS
TE-8M2O1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYexVW1VUUN3ME2xMlMyPDZ{IN88US=>NXjQWYVpW0GQR1XS
L-363MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvFRW1uUUN3ME2xMlM1OjB6IN88US=>Mn\uV2FPT0WU
EKVXMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITp[3VKSzVyPUGuN|Q2PjhizszNNE[yWZRUSU6JRWK=
SK-MEL-3NF;6NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH6TWM2OD1zLkS4OVU3KM7:TR?=M2C1OnNCVkeHUh?=
TGBC24TKBMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrWN2dKSzVyPUGuOVAyQTNizszNM3jPVnNCVkeHUh?=
NCI-H1770NFX0dmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTFwNUGxNVMh|ryPNGHB[Y5USU6JRWK=
HuH-7M1jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXe1UGo4UUN3ME2xMlYxODl6IN88US=>MlTLV2FPT0WU
HL-60MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwNk[5Nlgh|ryPNIPYXVFUSU6JRWK=
TE-1NXPR[VB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml[3TWM2OD1zLkewPVQ2KM7:TR?=MX\TRW5ITVJ?
LC-2-adMorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFwN{O4PFch|ryPM3rme3NCVkeHUh?=
LB647-SCLCM2LxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPFcYROUUN3ME2xMlc3PTh|IN88US=>M3Hhe3NCVkeHUh?=
NCI-H2171NUPifWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vwTGlEPTB;MT63O|cyPiEQvF2=MVfTRW5ITVJ?
SK-PN-DWM2na[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLXTWM2OD1zLkmxNlk5KM7:TR?=Mn3OV2FPT0WU
MC-IXCNFzwNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;0TWM2OD1zLkm4PVgh|ryPM1n4bXNCVkeHUh?=
LS-513MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTJwMEWzNFUh|ryPNYLKNZMzW0GQR1XS
EW-3Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7ISW5KSzVyPUKuNFk5PDRizszNMlTZV2FPT0WU
OPM-2M2fjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTJwMUCyJO69VQ>?MXfTRW5ITVJ?
LP-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjjO4hIUUN3ME2yMlI2QDB5IN88US=>Mn:2V2FPT0WU
LU-134-AMkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXVU2tKSzVyPUKuNlc4KM7:TR?=NVzLbnhQW0GQR1XS
CP66-MELMn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTuW3JCUUN3ME2yMlI6ODF2IN88US=>MoDwV2FPT0WU
HCC1143NWPRU3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYD4NWF4UUN3ME2yMlQ2OzZ6IN88US=>M{CzXnNCVkeHUh?=
LOXIMVINF7iPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LvV2lEPTB;Mj62NFIyKM7:TR?=NXq5THN3W0GQR1XS
TE-10MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTJwN{C4N|gh|ryPNUm1fWVyW0GQR1XS
NCI-H1882MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJwN{WyNlch|ryPNFnlOJRUSU6JRWK=
CHP-126NFnud4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn2NG1KSzVyPUKuO|Y{OTdizszNM1XacnNCVkeHUh?=
NCI-H1623M2\DTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJwOUKwNlQh|ryPMWrTRW5ITVJ?
GB-1NED2dXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHviZ3dKSzVyPUKuPVM1ODRizszNMXPTRW5ITVJ?
RCC10RGBMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV[3eVRTUUN3ME2yMlk2OjhzIN88US=>MnnUV2FPT0WU
NCI-H2141NY\VSHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITNUWxKSzVyPUKuPVY5QTZizszNM1rOUnNCVkeHUh?=
GI-ME-NM{O4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\4RnVbUUN3ME2zMlAxPTZ3IN88US=>MkGzV2FPT0WU
NCI-H526NFW0UpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTNwMESwPFUh|ryPMVrTRW5ITVJ?
NCI-H747NVfWToRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXxc2dbUUN3ME2zMlA1QTl{IN88US=>Mmi3V2FPT0WU
SNU-423MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYCwd3ZKUUN3ME2zMlIxOzF|IN88US=>NGDSUnJUSU6JRWK=
A427MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPwZWdxUUN3ME2zMlI2Pjl7IN88US=>MnPzV2FPT0WU
CAL-12TM3;od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4ntT2lEPTB;Mz60NFcyOyEQvF2=M3zjbnNCVkeHUh?=
LU-99ANFjoXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTNwNEexNFUh|ryPMknvV2FPT0WU
MS-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4j5TWlEPTB;Mz61N|QzQSEQvF2=M4[zVHNCVkeHUh?=
SK-LU-1NWnEfFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3X0SmlEPTB;Mz63OlI6PSEQvF2=M3LMeXNCVkeHUh?=
SW837M3f1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfpTWM2OD1|Lke2N|M{KM7:TR?=NID1NYRUSU6JRWK=
ES8MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTNwOEO4O|ch|ryPNH\GSpdUSU6JRWK=
MZ2-MELMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTNwOUKwPFYh|ryPMlP6V2FPT0WU
TGWNXn3RnhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3v0VGlEPTB;ND6wNVMyOSEQvF2=MYfTRW5ITVJ?
GP5dMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTRwMEWzOlIh|ryPMorEV2FPT0WU
BB49-HNCMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUf3ZVU2UUN3ME20MlE2OjF|IN88US=>NH2zXItUSU6JRWK=
NB13MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETjSW5KSzVyPUSuNlY5QDdizszNM131U3NCVkeHUh?=
NTERA-S-cl-D1NUS1Z3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NID2XlZKSzVyPUSuNlg3OTVizszNNGTTUYxUSU6JRWK=
NCI-H1648MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TLTWlEPTB;ND6yPVgyQSEQvF2=MWrTRW5ITVJ?
LCLC-103HM2T1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVewcGh2UUN3ME20MlMzOTl3IN88US=>NF\BTlNUSU6JRWK=
LS-411NMmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\lUWlEPTB;ND60OFg5PSEQvF2=MlK2V2FPT0WU
NCI-H1092MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjaNW5KSzVyPUSuOFU3QDdizszNMV3TRW5ITVJ?
PANC-10-05MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWD2dHliUUN3ME20MlY6QDRizszNM3v1c3NCVkeHUh?=
DK-MGM1qwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:3TWM2OD12LkiwPVM{KM7:TR?=NWfuV|JsW0GQR1XS
OVCAR-5M{e2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG[3SZBKSzVyPUSuPFEzOjZizszNNXuwRWp2W0GQR1XS
CAL-39NUPGeVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfBTWM2OD12Lki3Olch|ryPMkX4V2FPT0WU
TE-441-TMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrHPXNEUUN3ME20MlkxPTN5IN88US=>M{fITXNCVkeHUh?=
MOLT-16NFPBdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vuXmlEPTB;ND65OVI2OyEQvF2=MWHTRW5ITVJ?
MCF7M1fVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXpbGRZUUN3ME21MlE1PTF5IN88US=>MlnWV2FPT0WU
CAPAN-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUe1NVhbUUN3ME21MlI2PzB5IN88US=>NHTLbZZUSU6JRWK=
PSN1NXPvOmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LkVGlEPTB;NT6yO|I{PSEQvF2=MlvtV2FPT0WU
NCI-H292MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXH[4l2UUN3ME21MlMxODR2IN88US=>M4jTXXNCVkeHUh?=
CPC-NMnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTkPYJJUUN3ME21MlM6PDF7IN88US=>NGO2b3ZUSU6JRWK=
DoTc2-4510MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjDdpZKSzVyPUWuOFU{PzFizszNMojZV2FPT0WU
LB1047-RCCNFu4SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{G1b2lEPTB;NT61OVk{OyEQvF2=NYrmRW9JW0GQR1XS
MHH-ES-1NXjzeGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjGZYs{UUN3ME21MlU6QTB5IN88US=>NY\0V|J4W0GQR1XS
NMC-G1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTVwN{CyNlch|ryPNHTaTGZUSU6JRWK=
SW1710MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TIZ2lEPTB;NT63OFc2OSEQvF2=NGnhdWFUSU6JRWK=
YAPCMlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDueZZKSzVyPUWuO|YzODFizszNMXjTRW5ITVJ?
22RV1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjINpBbUUN3ME21MlgxODF7IN88US=>NVvvNll{W0GQR1XS
COLO-679M4jofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfqcGpKSzVyPUWuPFg6PDhizszNNYjhNYFxW0GQR1XS
TCCSUPM2T1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTrTWM2OD13LkmzNlU6KM7:TR?=NF;JUpdUSU6JRWK=
C2BBe1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\5UoRKSzVyPUWuPVM6PyEQvF2=NVf3WXV1W0GQR1XS
TE-15NIm4dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTkcWdKSzVyPU[uNFY3ODVizszNMkf2V2FPT0WU
SCLC-21HMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnTUY9lUUN3ME22MlExQDR|IN88US=>M3TKRnNCVkeHUh?=
EoL-1-cellNXTBVFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LHdGlEPTB;Nj6xOlU3OyEQvF2=MnLpV2FPT0WU
NKM-1Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPNd|VKSzVyPU[uNVY4OSEQvF2=Mm\5V2FPT0WU
NCI-H1304NX7RWVBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfhS2FKSzVyPU[uNlc1OjhizszNNEfBZoNUSU6JRWK=
NB6MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPBTWM2OD14LkK5OlIzKM7:TR?=NIP2[|VUSU6JRWK=
NALM-6MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPhSnFKSzVyPU[uN|MzOyEQvF2=Mo\wV2FPT0WU
NCI-H522M4TURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjnbXp{UUN3ME22MlM{OzB4IN88US=>MXTTRW5ITVJ?
MV-4-11M4T4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2m5SWlEPTB;Nj6zO|A4QSEQvF2=MnfqV2FPT0WU
LB2241-RCCNXu5cpZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXEO5ZKSzVyPU[uN|g3PjdizszNMYLTRW5ITVJ?
NCI-H1417MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjRbmRyUUN3ME22MlQxQDR5IN88US=>NHHiO|lUSU6JRWK=
HT-1197MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIm0ZYdKSzVyPU[uOVcyOjJizszNMoPJV2FPT0WU
P30-OHKNEjhU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfpTWM2OD14Lk[yO|ch|ryPNWf1Z4tKW0GQR1XS
ALL-PONEHDWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTZwN{G5NVYh|ryPM2XL[HNCVkeHUh?=
OVCAR-4MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\Bc5V7UUN3ME22Mlc2PDB3IN88US=>NYHuNVFiW0GQR1XS
HCC2157NGfhNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Wxc2lEPTB;Nj63O|Q4PSEQvF2=M3zKb3NCVkeHUh?=
NCI-H838MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;zTVdKSzVyPU[uPVY1QSEQvF2=M33U[nNCVkeHUh?=
NCI-H1299M3vybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrIPYJ{UUN3ME22Mlk4ODlizszNNEnPTlVUSU6JRWK=
SW954MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zxTGlEPTB;Nz6yNFA3QCEQvF2=M{HOUnNCVkeHUh?=
NCI-H441NEPQTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDxZ4U3UUN3ME23MlM1ODZ3IN88US=>M1zPVXNCVkeHUh?=
SK-MEL-2MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTPNHVKSzVyPUeuOFg{PzNizszNMlfNV2FPT0WU
KARPAS-45NEjHNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELkNHJKSzVyPUeuOlU6OjlizszNM3jNcnNCVkeHUh?=
CAL-54NXPnO3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX[xbIhqUUN3ME23MlgzQTd5IN88US=>Ml7KV2FPT0WU
KYSE-180M{nSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTdwOEi5OFEh|ryPNYDWeIhHW0GQR1XS
NCI-H187MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4n5WWlEPTB;Nz65OVk1PyEQvF2=MVrTRW5ITVJ?
RT-112MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRThwMEm2O|ch|ryPMWjTRW5ITVJ?
NCI-H1437MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETBd2xKSzVyPUiuNFk4QTVizszNM2e0bXNCVkeHUh?=
SNU-449MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3sOGhKSzVyPUiuNlgzPzJizszNMWDTRW5ITVJ?
HCC1187Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7NTWM2OD16LkK5N|kyKM7:TR?=MkHaV2FPT0WU
NCI-H2030NV6wfGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRThwM{e3NVQh|ryPNXTaUWZxW0GQR1XS
HuO-3N1Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlexTWM2OD16LkO3PFQ1KM7:TR?=NXPxO2FKW0GQR1XS
COLO-792MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;hTWM2OD16LkSxOVI4KM7:TR?=MlfwV2FPT0WU
MIA-PaCa-2NGXM[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXOTWM2OD16Lki1OVA5KM7:TR?=MWXTRW5ITVJ?
SK-N-FINFmwXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGj6[ndKSzVyPUmuNFQzPSEQvF2=NX;BZWNiW0GQR1XS
MMAC-SFM4Dudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHlTWM2OD17LkC5O|UyKM7:TR?=Mo\PV2FPT0WU
NCI-H28NF\IeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3JTWM2OD17LkGwOFY6KM7:TR?=NEf3UFJUSU6JRWK=
ETK-1NETPcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkC0TWM2OD17LkK5PVc1KM7:TR?=M2D0RnNCVkeHUh?=
NCI-H1993NV\qTYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTlwNESyOlEh|ryPNWWweXFqW0GQR1XS
no-11NH7icXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTlwNEexNkDPxE1?MojqV2FPT0WU
ChaGo-K-1NUnQS4E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmeyTWM2OD17LkWxOVg{KM7:TR?=NILGPVdUSU6JRWK=
NCCITMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTrTWM2OD17LkWzNVY6KM7:TR?=MWfTRW5ITVJ?
SASMn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFyLkK0PEDPxE1?NV;OZ|NnW0GQR1XS
A673NWn4RoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\E[WlKSzVyPUGwMlM4ODRizszNM{S4O3NCVkeHUh?=
NCI-H1522MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2OxVGlEPTB;MUCuN|cxPyEQvF2=NVfPfGhHW0GQR1XS
NCI-H810NF;POnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorWTWM2OD1zMD6zPVA4KM7:TR?=NVroUnh4W0GQR1XS
IST-MES1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFyLkS1OlQh|ryPMWfTRW5ITVJ?
GR-STMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1P2fGlEPTB;MUCuOVAzPCEQvF2=MnXWV2FPT0WU
SUP-T1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFyLkezNVch|ryPMnvmV2FPT0WU
NB5MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFyLkmwNlIh|ryPM3;pTXNCVkeHUh?=
MZ1-PCNIjhV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn1Zpd[UUN3ME2xNE46PTdzIN88US=>MmnQV2FPT0WU
SK-CO-1NV:0XYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LlSWlEPTB;MUCuPVk{OSEQvF2=M{\5TnNCVkeHUh?=
Capan-2M4Kz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFzLkOxPVgh|ryPNGn6T4RUSU6JRWK=
697NEPCbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33WbmlEPTB;MUGuOlc2PyEQvF2=MWPTRW5ITVJ?
REHNFTBTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4OxU2lEPTB;MUGuO|Q2OSEQvF2=MVTTRW5ITVJ?
GI-1M1zIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjXeW1EUUN3ME2xNU45PjF3IN88US=>M2PC[XNCVkeHUh?=
BB65-RCCM3HzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorHTWM2OD1zMj6wPVE3KM7:TR?=MUHTRW5ITVJ?
NCI-H1651MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzmZpFKSzVyPUGyMlI1PzhizszNNEHyOYNUSU6JRWK=
NCI-H1618M2izV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nmUmlEPTB;MUKuN|k4PiEQvF2=MWDTRW5ITVJ?
NCI-H2081NX\mVmxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7xOZJiUUN3ME2xNk43OTRzIN88US=>NVL2e3RnW0GQR1XS
GCIYM{To[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rENWlEPTB;MUKuO|IyOyEQvF2=M3\ySnNCVkeHUh?=
NYM2XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTF|LkC2OFMh|ryPMX3TRW5ITVJ?
PANC-03-27NULDb3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTF|LkC4NFch|ryPM362RXNCVkeHUh?=
BHYNWDFWog3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fUT2lEPTB;MUOuNlEzOSEQvF2=Mn21V2FPT0WU
SK-OV-3M1i5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnl[m5KSzVyPUGzMlM4PjNizszNNXqyWY03W0GQR1XS
5637NV\ZZ29PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTF|Lke3OVkh|ryPNF74NGpUSU6JRWK=
LC-1FNYjhNVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjCdotEUUN3ME2xOE4xOzV4IN88US=>NEP0OJNUSU6JRWK=
SNB75NH3KZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIX2OWNKSzVyPUG0MlA{QDNizszNNUPKb|ZnW0GQR1XS
CHP-212MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3T0VWlEPTB;MUSuNFQ3PCEQvF2=NWTMXGgyW0GQR1XS
HT-1376NXL4c29OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTF2LkGxNlYh|ryPMWDTRW5ITVJ?
MONO-MAC-6NYH6[2hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXwOGZKSzVyPUG0MlE2ODJizszNMnHrV2FPT0WU
CA46MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF2LkG4Nlch|ryPMn76V2FPT0WU
SCC-15NX3R[mIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnEVVBEUUN3ME2xOE42PTh|IN88US=>NVjmb3lKW0GQR1XS
ATN-1M3vBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7HTWM2OD1zND62OlI4KM7:TR?=Mn7PV2FPT0WU
NCI-H2405Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDXS|BKSzVyPUG0MlgyPTdizszNNIDMWFBUSU6JRWK=
NCI-H716NVPsfJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF2Lki0PVMh|ryPM2rtWXNCVkeHUh?=
SW620M2Dn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HXNWlEPTB;MUSuPVAyPCEQvF2=NFT5NZhUSU6JRWK=
NCI-H226MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\udoR7UUN3ME2xOE46ODh3IN88US=>M3fMbXNCVkeHUh?=
SW962NHvMfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHrNWJKSzVyPUG0Mlk1OzJizszNMmKyV2FPT0WU
KYSE-150NIG1[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPsUldlUUN3ME2xOE46PTVizszNMVHTRW5ITVJ?
OCUB-MMorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7GNVJRUUN3ME2xOE46QDh|IN88US=>MY\TRW5ITVJ?
ES7NHHSdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHSVWZZUUN3ME2xOU4xQTh2IN88US=>NHi0T4JUSU6JRWK=
SW1463NWfUWJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDRc4xuUUN3ME2xOU41OjJ|IN88US=>NG\TN2FUSU6JRWK=
CAKI-1NEDVfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTF3LkWzOFYh|ryPNVPrXW5XW0GQR1XS
MKN28MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTF3LkW0O|kh|ryPMlnmV2FPT0WU
SW13MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTF3Lk[xPEDPxE1?NWPUS4dXW0GQR1XS
A3-KAWMojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnPSnlDUUN3ME2xOU46Pjl5IN88US=>M1fPSnNCVkeHUh?=
LU-65M3HL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vv[GlEPTB;MUWuPVc3QCEQvF2=NFLUUW9USU6JRWK=
Calu-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1G5PGlEPTB;MU[uNFM3QCEQvF2=NIrFZ5BUSU6JRWK=
ST486NGrNU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTF4LkC0N|Eh|ryPMmjKV2FPT0WU
BB30-HNCNV3ReFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTF4LkGyOFYh|ryPNFzIdmhUSU6JRWK=
EGI-1M4HDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjXc5Z[UUN3ME2xOk41PDZizszNM132OXNCVkeHUh?=
SH-4MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXUeY9KSzVyPUG2MlQ4OzFizszNMnvsV2FPT0WU
MN-60MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPQ[Y9KSzVyPUG3MlIzQTdizszNMlyzV2FPT0WU
MPP-89MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPiNItKSzVyPUG3MlI1PTlizszNNVjm[XpzW0GQR1XS
A2780MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTF5LkSxN|kh|ryPNWD1c5RpW0GQR1XS
DaoyM2XT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTF5LkS2PVUh|ryPNVnuV2lLW0GQR1XS
NCI-H2126M321[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXP1WI5VUUN3ME2xO{41PzdzIN88US=>NF;WeXVUSU6JRWK=
NCI-H1563NXrMWYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV2xfWZmUUN3ME2xO{41QTF5IN88US=>M1PjUHNCVkeHUh?=
8-MG-BANUWzbHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTF5Lk[2OFgh|ryPNGL2cnVUSU6JRWK=
786-0MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LlfGlEPTB;MUeuPFM2OyEQvF2=MWDTRW5ITVJ?
AM-38NH7aUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTMT5E4UUN3ME2xO{46OzB4IN88US=>M{PScnNCVkeHUh?=
COLO-824M3;KTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorkTWM2OD1zOD60OFM3KM7:TR?=NU\1S5pQW0GQR1XS
SK-MEL-30NVnCVGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\JTIdKSzVyPUG4MlUxQDJizszNNX\YbYtVW0GQR1XS
CESSNV7tS2J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPLOGFKSzVyPUG4Mlc3ODlizszNNGjEdo5USU6JRWK=
BL-70NYfmPG9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF6LkixOVYh|ryPNVK1e4x5W0GQR1XS
NCI-H2170M3HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTF6LkmxO|kh|ryPNHHKXZhUSU6JRWK=
HT-3NHe1TY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3SeW84UUN3ME2xPE46QDNizszNM4rq[nNCVkeHUh?=
BOKUM1\ucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDqTWM2OD1zOT6wN|gyKM7:TR?=MoXHV2FPT0WU
HPAF-IINFjkV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PWNWlEPTB;MUmuN|AyPSEQvF2=MVvTRW5ITVJ?
KGNNGfqSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rwTmlEPTB;MUmuOFc3PSEQvF2=NYTwS29XW0GQR1XS
MC-CARMlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XJN2lEPTB;MUmuOlMyOyEQvF2=NEDhT29USU6JRWK=
BHT-101MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PDfGlEPTB;MUmuO|c4KM7:TR?=NVHHb3NYW0GQR1XS
SW1783MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjXTWM2OD1zOT63PFA3KM7:TR?=MkToV2FPT0WU
KP-N-YNMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjjSIlKSzVyPUKwMlAzPjJizszNMmm4V2FPT0WU
LU-165Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTJyLkW1O|Eh|ryPNVexZpJ7W0GQR1XS
GOTOMoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjqOGZWUUN3ME2yNE43PDVzIN88US=>NFK2VI5USU6JRWK=
EFM-19M4rpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;KTWM2OD1{MT6wO|E3KM7:TR?=NFTOUFJUSU6JRWK=
CTV-1Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XHV2lEPTB;MkGuNVA2PCEQvF2=MmPDV2FPT0WU
HELNHzrSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjHXVdnUUN3ME2yNU41OjF4IN88US=>NGr4U|NUSU6JRWK=
SNU-C2BNFSySXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJzLkSyOkDPxE1?MlPOV2FPT0WU
ECC4NGWyZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPETWM2OD1{MT63NFch|ryPNFfleFdUSU6JRWK=
NEC8NW[1NohGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ewNGlEPTB;MkGuPFM3QCEQvF2=MljxV2FPT0WU
KMOE-2NFvOcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTYV211UUN3ME2yNU45QTJzIN88US=>NVXXdXEyW0GQR1XS
NCI-H524M2DnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTJ{LkC4NFgh|ryPMlHyV2FPT0WU
WSU-NHLNXS3b21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWWxeJN1UUN3ME2yNk4yPTd5IN88US=>NVXGWm1yW0GQR1XS
SF126M4fzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojUTWM2OD1{Mj6yOFY6KM7:TR?=M1izTXNCVkeHUh?=
HOP-92NUX1SlNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDmTWM2OD1{Mj6zNVY4KM7:TR?=NF7oS2hUSU6JRWK=
CTB-1M1e5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInpfm5KSzVyPUKyMlQ3PzdizszNMX3TRW5ITVJ?
KYSE-270MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHMTnpKSzVyPUKyMlk{PTdizszNMXHTRW5ITVJ?
SK-MEL-24MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPTWnptUUN3ME2yN{4yQDdizszNNFqyepRUSU6JRWK=
Calu-3MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHKxOZJKSzVyPUKzMlIyOjhizszNM3PQRXNCVkeHUh?=
GAMGNIPD[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLQeFNnUUN3ME2yN{4zOzZ5IN88US=>MYHTRW5ITVJ?
SW1573MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfZVnRKSzVyPUKzMlc1OTVizszNNFOwSGpUSU6JRWK=
MHH-NB-11MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJ2LkCxPVQh|ryPNYLPUmdPW0GQR1XS
TK10M4\zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjoTWM2OD1{ND61NFE{KM7:TR?=M4ewTXNCVkeHUh?=
LB373-MEL-DMlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFOzVW9KSzVyPUK0MlYxPjRizszNMlr3V2FPT0WU
KALS-1MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzRVJRkUUN3ME2yOE44OzJ5IN88US=>NXjhVnZnW0GQR1XS
HUTU-80M1frTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ3LkiwN|Ih|ryPMXPTRW5ITVJ?
HuP-T3M17E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnMbHVKSzVyPUK2MlE3PzRizszNNVfK[IUxW0GQR1XS
OE19NGfm[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml6zTWM2OD1{Nj6yNVU{KM7:TR?=MULTRW5ITVJ?
J82MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJ4LkK0O|Eh|ryPMlXFV2FPT0WU
DU-4475MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTpTWM2OD1{Nj6zPFE6KM7:TR?=NVvoRow4W0GQR1XS
DMS-53NWrUSlduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;STWM2OD1{Nj61NVM5KM7:TR?=NFLVeGRUSU6JRWK=
COLO-741MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTJ4LkizOFQh|ryPMlvrV2FPT0WU
SW48MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPMfJdKSzVyPUK2Mlg5OiEQvF2=NGr5TodUSU6JRWK=
IGR-1M37COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTJ4LkmzN|Qh|ryPNFfUR4JUSU6JRWK=
639-VMmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTJ5LkCyOFUh|ryPNFfWfVdUSU6JRWK=
LK-2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXJTWM2OD1{Nz60NVQyKM7:TR?=MXvTRW5ITVJ?
NCI-H2347MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\WdJBGUUN3ME2yO{46Pjl7IN88US=>MWfTRW5ITVJ?
NCI-H2228M1rpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTJ6LkC5NFUh|ryPM{nxN3NCVkeHUh?=
LS-123NVvpU|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkD6TWM2OD1{OD6xNlYzKM7:TR?=Mo\uV2FPT0WU
U031MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rBSGlEPTB;MkiuNlUzKM7:TR?=NFnpOJNUSU6JRWK=
NCI-H1792NX\QUYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3z6U2lEPTB;MkiuOFczOSEQvF2=NGLSfJBUSU6JRWK=
NCI-H2087NWP1W|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPuTWM2OD1{OD63OVUzKM7:TR?=M1XYbXNCVkeHUh?=
NCI-H2342MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJ7LkWyNFgh|ryPNWnOOWwyW0GQR1XS
SW626MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXL5e4dIUUN3ME2yPU44PTZizszNM{PaU3NCVkeHUh?=
LB2518-MELNHu3NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnm3TWM2OD1{OT64NVUh|ryPMmX1V2FPT0WU
RXF393M4\QRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTNyLkC5OVIh|ryPMn:4V2FPT0WU
LC4-1NVTTVHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjocohKSzVyPUOwMlMxQTJizszNNWjjRYxtW0GQR1XS
NCI-H1694NF;yXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnyTWM2OD1|MD62OlI1KM7:TR?=NYTBSnJnW0GQR1XS
K5NYHVXHU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVWwWIpTUUN3ME2zNE46PzB{IN88US=>NFzqXVFUSU6JRWK=
HDLM-2MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TmZmlEPTB;M{CuPVczPSEQvF2=M2[wfHNCVkeHUh?=
BCPAPMlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLlXVZKSzVyPUOxMlg{PzlizszNNF71dGtUSU6JRWK=
BC-3NVnONVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7Yd|hKSzVyPUOyMlE1ODNizszNM2C0ZnNCVkeHUh?=
LB996-RCCMlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTN{LkKzOVgh|ryPNXrBWJFEW0GQR1XS
NCI-H2009Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHHTWM2OD1|Mj60PVgyKM7:TR?=M3fkSXNCVkeHUh?=
HTC-C3NFPZXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEO1ZplKSzVyPUOzMlc2OTlizszNM32wbnNCVkeHUh?=
LAMA-84NFfBbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUS3b3hUUUN3ME2zOE41PDB5IN88US=>NXHIZWpYW0GQR1XS
CCRF-CEMMnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\uTWM2OD1|ND61O|E2KM7:TR?=NEHFXmFUSU6JRWK=
AN3-CAMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPTUY5KSzVyPUO1MlA2PjhizszNNHTGN3dUSU6JRWK=
NCI-H1734NXvz[pJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTQU5RKSzVyPUO1MlI2PjFizszNMorNV2FPT0WU
Ca-SkiNYjkXmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTN3LkSxNFEh|ryPMV;TRW5ITVJ?
U-266MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTN3Lk[xNVQh|ryPMoP2V2FPT0WU
SBC-5NFjoNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4j1e2lEPTB;M{WuO|c5OSEQvF2=MkDmV2FPT0WU
GT3TKBM4nLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPPZXZTUUN3ME2zO{4yOTVizszNM164O3NCVkeHUh?=
MDA-MB-175-VIINEOzOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PuN2lEPTB;M{euNlI1QCEQvF2=M{\LUXNCVkeHUh?=
PFSK-1M2TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LNeGlEPTB;M{euNlQ{PSEQvF2=NVvQV294W0GQR1XS
IMR-5NFf0dIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfaTWM2OD1|Nz6yOFg4KM7:TR?=MW\TRW5ITVJ?
DaudiNFXJNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjxUlJKSzVyPUO3MlM2QTdizszNMoXKV2FPT0WU
A498NUjjVmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrCW3Q2UUN3ME2zO{44OjF6IN88US=>M1Xqb3NCVkeHUh?=
SCC-4MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrSV5JjUUN3ME2zO{44QDR|IN88US=>NXH3UI42W0GQR1XS
COLO-680NMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLhb3VKSzVyPUO4MlI5QDVizszNNX35PJdxW0GQR1XS
SK-MES-1M{LsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13ySmlEPTB;M{iuN|IyPSEQvF2=NXzMNFlRW0GQR1XS
SRMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTN6LkW0PVUh|ryPMmrYV2FPT0WU
LNCaP-Clone-FGCM3Lwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\4RZR[UUN3ME2zPE42PjN5IN88US=>NE\EVZFUSU6JRWK=
SK-HEP-1NIH2bFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTN6Lke4NlIh|ryPNEXrW3FUSU6JRWK=
BPH-1NEX1RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTN6LkizNlkh|ryPNVPWNmJpW0GQR1XS
NCI-H1755MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTKTWM2OD1|OT61PFE4KM7:TR?=NHnE[|hUSU6JRWK=
LXF-289NUDVO|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTN7LkiwPFQh|ryPNXzSSodIW0GQR1XS
SW1088MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGezS5hKSzVyPUSwMlIyODdizszNNX;rb3UxW0GQR1XS
MOLT-4MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPmdlVnUUN3ME20NE4zQTBzIN88US=>MlLOV2FPT0WU
AsPC-1M1zKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTRyLkS1PFMh|ryPMmPYV2FPT0WU
HOP-62MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXGxSJFCUUN3ME20NE43PTZ6IN88US=>NEPFVG9USU6JRWK=
A172MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT1cYd5UUN3ME20NE45PTFzIN88US=>MmH1V2FPT0WU
SN12CNX35ZnBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\2TWM2OD12MD65N|g2KM7:TR?=M3jZeXNCVkeHUh?=
MDA-MB-231M{W1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;zcWlEPTB;NECuPVg6QCEQvF2=MmfsV2FPT0WU
RPMI-2650M2ToOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTRzLkG1PVMh|ryPM4XZZXNCVkeHUh?=
KYSE-140NFPZ[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2m0VGlEPTB;NEGuPFEzOyEQvF2=MkfRV2FPT0WU
KINGS-1NWK1OGlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTR{LkS2PVch|ryPNFi1S|ZUSU6JRWK=
HSC-3NXLRVmQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjLd5hKSzVyPUSyMlY3PjFizszNMWnTRW5ITVJ?
PC-14NGHENXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTR|LkG4PFIh|ryPMlTBV2FPT0WU
COR-L105NITxOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvYUVNKSzVyPUSzMlY2ODJizszNMULTRW5ITVJ?
BE-13MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLweGNKSzVyPUS0MlI{PzFizszNMWrTRW5ITVJ?
NCI-H661MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3aT2hKSzVyPUS0MlI6PThizszNMk\IV2FPT0WU
IST-MEL1NULPZVl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rtRWlEPTB;NESuN|U6QSEQvF2=MkjnV2FPT0WU
HCC1806MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPMdYhKSzVyPUS0MlU5PzNizszNNV6xSm5SW0GQR1XS
COLO-800MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTR2Lki0OVMh|ryPMYXTRW5ITVJ?
IST-SL2M1rTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXK3N4ZUUUN3ME20OU4yOjR5IN88US=>MmHlV2FPT0WU
8305CM2HDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjnVFJKSzVyPUS1MlMxQSEQvF2=M4\CXnNCVkeHUh?=
UACC-62NVzQ[mRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTR4LkK4O|Uh|ryPNFfhSm5USU6JRWK=
COR-L23M1q1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3T4VWlEPTB;NEeuNVk6KM7:TR?=MVPTRW5ITVJ?
EFE-184MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml21TWM2OD12Nz6zPFgh|ryPMmewV2FPT0WU
DMS-114Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fie2lEPTB;NEeuOFE1QSEQvF2=MVHTRW5ITVJ?
KYSE-520M122c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTR6LkWzNVUh|ryPM4fiZXNCVkeHUh?=
SNG-MM4i3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jnTGlEPTB;NEmuOFM1KM7:TR?=NIX4[YpUSU6JRWK=
A2058MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXqyRWc6UUN3ME20PU41QDh3IN88US=>MVrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

Cell Assay: [1]

Cell lines MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
Concentrations 0.02-0.8 μM
Incubation Time 3 days
Method For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

Animal Study: [1]

Animal Models IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
Formulation 25 mM tartaric acid
Dosages 25 mg / kg and 75 mg / kg
Administration Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.

[2] McKinley ET, et al. Clin Cancer Res, 2011, 17(10), 3332-3340.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research a  ...more University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

view more

Chemical Information

Download OSI-906 (Linsitinib) SDF
Molecular Weight (MW) 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • AG-1024

    AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us